Cirrhosis
Disease6 papers2 findings
- Human trial1
- Humans2
Associations
2GLP-1 receptor agonists
downin humans1HR 0.787
1 study
GLP-1 receptor agonists
downin humans1HR 0.787
GLP-1 receptor agonists lower the risk of cirrhosis in humans (HR, 0.787; 95% CI, 0.619-0.999).
Humansliver transplant recipients with diabetes
Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial · Metabolism: clinical and experimental · 29 Sep 2026
Antiviral therapy
downin humans1
1 study
Antiviral therapy
downin humans1
Antiviral therapy lowers the risk of cirrhosis in humans.
Reviewin HBV infection
Review Article: Cancer Surveillance for Early Detection of Liver Cancer in Patients with HBV Infection · Alimentary pharmacology & therapeutics · 29 Sep 2026
Latest
13Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis
Multimorbidity Patterns and Cluster Characteristics Among People Living with HIV in the Korean HIV/AIDS Cohort, 2006-2023
AGA Clinical Practice Update on Surveillance of Pancreatic Cystic Lesions and Hepatocellular Carcinoma in Older Adults: Expert Review
Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with…Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.